The company did a very poor job in their press release of providing a status update on their projects.
They also did a poor job in the conference call of addressing the $2MM write off. They should have admitted to making a mistake that led to this charge rather than dancing with words. I sold off 30% of my holdings this morning for this reason alone.
I am pleased with their progress and with how aggressive they are moving towards an immediate product launch if/when they get FDA approval. Let's hope the device doesn't have to go to FDA panel review.
I 100% expect a secondary stock offering and related dilution a couple of months after FDA approval.